Loading stock data…
$268.43-2.74 (-1.01%)
Illumina, Inc.
Illumina, Inc. in the Healthcare sector is trading at $271.18 with a market capitalization of $31.9B. Wall Street consensus targets $236.55 (20 analysts), implying a -12.8% move over the next 12 months. The stock is currently near its 52-week high of $309.35, remaining 61.8% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $1.09B↓ | $1.16B↑ | $1.08B↑ | $1.06B |
| Gross Profit | — | $721.00M↓ | $759.00M↑ | $733.00M↑ | $695.00M |
| Operating Income | — | $209.00M↓ | $211.00M↓ | $227.00M↑ | $214.00M |
| Net Income | — | $134.00M↓ | $334.00M↑ | $150.00M↓ | $235.00M |
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consu...